Finding cancer targets for liver cancer immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of primary liver cancer (HCC) or another type of cancer.
- You must be 18 years or older.
- You must be able to give written permission (informed consent) to participate.
- If you are a healthy volunteer, you must be 80 years or older and have no history of any cancer treatment or diagnosis.
- You cannot have an active infection that requires antibiotics.
- You cannot have a pre-cancerous condition if you are a healthy volunteer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.